PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
5.61%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 1.13%. Joel Greenblatt would investigate if growth quality matches quantity.
5.26%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 0.95%. Jim Chanos would check for structural cost disadvantages.
7.07%
Growth of 7.07% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
1.38%
Margin change of 1.38% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.54%
Other expenses change of 74.54% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
4.38%
Operating expenses growth 50-90% of Medical - Pharmaceuticals median of 6.79%. Mohnish Pabrai would examine discipline.
5.11%
Total costs growth 50-90% of Medical - Pharmaceuticals median of 7.05%. Mohnish Pabrai would examine discipline.
No Data
No Data available this quarter, please select a different quarter.
72.30%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 2.07%. Jim Chanos would check for overinvestment.
-19.43%
EBITDA decline while Medical - Pharmaceuticals median is -6.67%. Seth Klarman would investigate causes.
-23.71%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
18.46%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
12.17%
Margin change of 12.17% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
74.13%
Other expenses change of 74.13% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
23.10%
Pre-tax income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
16.56%
Margin change of 16.56% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-16.79%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
42.27%
Net income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
34.71%
Margin change of 34.71% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
42.25%
EPS change of 42.25% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
42.25%
Diluted EPS change of 42.25% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.02%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.01%. Seth Klarman would investigate strategy.